HALFAN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jul 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 26m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALFAN is an oral small-molecule tablet approved by GSK in 1992 for an undisclosed indication. The specific mechanism of action and therapeutic area are not publicly detailed in this dataset.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); commercial team likely in harvest/transition mode with reduced headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the mature, LOE-approaching status of HALFAN. Careers on this product involve defending market share against generics and optimizing profitability during transition to post-LOE phase.
Brand ManagerField Sales Representative
Worked on HALFAN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.